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Pharmacovigilance (PV) is based on the medical assessment of 
adverse medical events or drug-related problems, collected within 
organised health programmes. The large number of different PV 
systems, the equally large number of stakeholders within such 
systems (pharmaceutical companies, government regulatory bodies, 
national and international clinical regulatory bodies, healthcare 
workers, etc.), and the significant number of dimensions along 
which the effectiveness and efficiency could be measured, adds to 
this complexity. Furthermore, the lack of a standardised reporting 
protocol across the various PV systems hinders efforts to manage PV 
coherently on a global scale. This paper proposes the value of a 
standardised global PV reporting system by evaluating the systemic 
effects of the lack of such a standardised system. 
OPSOMMING 
Farmakologiese waaksaamheid (PV) is gebaseer op die mediese 
assessering van nadelige mediese gebeure of dwelmverwante 
probleme wat deur georganiseerde gesondheidsprogramme 
versamel word. Die groot aantal verskillende PV-sisteme, die ewe 
groot aantal belanghebbendes in sulke stelsels (farmaseutiese 
maatskappye, regerings, nasionale en internasionale kliniese 
reguleringsliggame, gesondheidswerkers, ens.), en die aansienlike 
aantal dimensies waarvolgens die effektiwiteit en doeltreffendheid 
gemeet kan word, dra by tot hierdie kompleksiteit. Verder 
belemmer die gebrek aan ’n gestandaardiseerde rapporterings-
protokol wat oor die verskillende PV-sisteme strek die pogings om 
PV op ’n wêreldwye skaal konsekwent te bestuur. Hierdie artikel 
stel die waarde van ’n gestandaardiseerde globale PV 
rapporteringsprotokol voor deur die sistematiese gevolge van die 
gebrek aan so ’n gestandaardiseerde stelsel te evalueer 
 
1 INTRODUCTION 
No medication is inherently safe: each treatment situation is unique, and each patient can respond 
differently to a specific treatment. The pharmacodynamics of biologics and chemically synthesised 
drugs on a molecular level are numerous and intricate; and it is resource-intensive to fully 
characterise the interactions of a drug in vitro. The topic of drug safety was brought to the world’s 
attention when, in the late 1950s, thousands of babies in the United Kingdom were born with 
congenital deformities (phocomelia) after in utero exposure to the seemingly safe drug Thalidomide. 
Thalidomide was originally marketed in 1957 as a sedative, but was also prescribed for pregnant 
women to alleviate the symptoms of morning sickness that are associated with the early stages of 
pregnancy. The World Health Organization (WHO) established the International Drug Monitoring 
Programme (IDMP) in 1968, in direct response to the Thalidomide tragedy [1]. 
 
Pharmacovigilance (PV) is based on the medical assessment of adverse medical events or drug-
related problems, collected within organised health programmes. Within these programmes it is 
vital to be able consistently to identify the nature of events, their severity, and their likelihood of 
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occurrence, and to assess causality in connection with the suspected drug(s) or medicine(s). An 
adverse drug reaction (ADR) is defined as being any undesirable effect of a medication beyond its 
intended therapeutic effect [2]. PV is a responsibility that is shared by all stakeholders in the health 
system, from pharmaceutical multinationals and regulatory agencies to healthcare professionals 
(HCPs) and the patients themselves. 
 
A PV system can be understood as consisting of an ADR reporting mechanism, data collation, 
causality analysis, risk assessment, decision-making, deliberated design and implementation of the 
appropriate action, and the evaluation of the outcomes achieved [3]. 
 
Standardisation is a principal tool used in quality improvement initiatives that focus on cost 
reduction and on identifying and eliminating inefficiencies within systems [4]. The concept of 
standardisation is broad, and spans multiple domains [5]. The standardisation of a system must be 
performed by subject matter experts from each of the various domains included in the system, along 
with a wide variety of stakeholders who have a vested interest in the system. 
 
This paper aims to connect the potential benefits of a standardised reporting system with the 
challenges brought about by the fragmented nature of the current global PV context. A review of 
the literature on ADR reporting shows that the traditional method of spontaneous reporting is not 
effective, and gives rise to a variety of problems such as poor data quality and insufficient data 
capturing due to the under-reporting of ADRs by both HCPs and patients.  
2 CONTEXT 
For a medicine or therapeutic drug to gain approval from clinical regulatory bodies and to receive 
marketing authorisation, it must meet stringent requirements and pass multiple stages of pre-
clinical and clinical trials. On completion of these trials, the regulatory body conducts a 
comprehensive review of the drug in question, to assess its potential benefits and harms. Once a 
drug has been approved and the marketing authorisation has been granted, the drug may be 
marketed within the jurisdiction governed by the relevant regulatory body. 
 
When a drug is marketed on a global scale, the number of patients using the drug can be in the order 
of millions. This presents an opportunity for a robust global PV system to receive large amounts of 
data from new patient groups through the spontaneous reporting of ADRs. With a large and multi-
ethnic1 population consuming medications, identifying new drug interactions is made more feasible. 
The consumption of a medication across a large population would also allude to the effects of 
consumption at different dosages and via different administration routes (intravenous, inhalation, 
oral, etc.). 
 
The current global PV landscape is complex. A simplified view can be seen in Error! Reference 
source not found.. The Uppsala Monitoring Centre (UMC), founded in 1978 by the WHO to support 
the Programme for International Drug Monitoring, coordinates PV activities among 127 member 
countries. It facilitates the development of PV systems in 28 associate member countries. 
 
The UMC manages and maintains the ADR database, VigiBase, which receives ADR reports from all 
the WHO member countries. In 2015, the VigiBase database had about 11 million ADR reports from 
120 countries [6]. The International Society for Pharmacovigilance (ISoP in Figure 1) plays a 
supportive role in providing educational and administrative advice to many pharmaceutical 
manufacturers and many countries with PV systems. Two notable regulatory authorities are the FDA 
(Food and Drug Administration) of the US, which makes use of the FDA Adverse Event Reporting 
System (FAERS); and the EMA (European Medicines Agency), which manages the Eudra-Vigilance 
reporting system. Countries that fall outside the regulatory jurisdiction of the FDA and EMA typically 
have their own Departments of Health (DoH) and respective National Regulatory Authorities (NRA) 
that co-ordinate PV activities on a national level. 
 
 
                                                     
1  Different ethnic groups could respond differently to certain medications, due to the effects of slight 
variations in their DNA, known as single nucleotide polymorphisms [37]. 
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Figure 1: Schematic representation of the current global PV landscape. 
The fragmented nature of PV in the global context presents the UMC with a multitude of challenges. 
Currently, problems such as under-reporting and the communication of incomplete, 
unrepresentative, and uncontrolled data prove to be significant barriers to detecting and 
characterising new adverse drug interactions and ADRs [7]. A 2016 study by Bailey et al. [8] identified 
108 ADR reporting systems and highlighted a number of challenges associated with the lack of a 
standardised ADR reporting form. 
3 REPORTING METHODS AND THE EFFECTS OF A LACK OF STANDARDISATION 
Data management is a key principle of pharmacovigilance. Sources of data include non-clinical and 
clinical trials, the scientific literature, pharmacoepidemiologic studies, and spontaneous reporting 
systems. Pharmacovigilance reporting systems rely primarily on the generation and detection of 
signals — that is, the communication of an ADR or adverse drug event (ADE) made by a patient, 
manufacturer, or healthcare provider to the appropriate PV centre. The unsolicited or spontaneous 
reporting of such ADRs is the cornerstone of data generation in post-marketing drug safety and 
surveillance. However, research suggests that spontaneous reporting is not a sufficiently 
comprehensive method of generating the data needed to make quantitative conclusions about the 
safety of medicines in the long term ([9],[10],[11]). 
3.1 Reporting methods 
There are three primary methods of reporting ADRs and drug safety information. The first is 
spontaneous reporting (SR). The other two are active surveillance methods: cohort event monitoring 
(CEM) and targeted spontaneous reporting (TSR). 
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3.1.1 Spontaneous reporting 
Spontaneous reporting during the post-marketing phase generates the majority of drug safety data, 
even more so than the clinical trials during the drug development process [12]. Lester et al. [12] 
found that between 52 and 55 per cent of drug label changes were the result of spontaneous 
reporting; this demonstrates the significance of spontaneous reporting in PV activities. Spontaneous 
reporting involves the unsolicited generation of a signal by a healthcare provider or a patient relating 
to the suspicion of an ADR. This method is better than active surveillance methods because it incurs 
little or no administrative cost; it covers a large population of potential reporters and a large profile 
of drugs; and it allows for the monitoring of a medicine throughout its entire life cycle. 
3.1.2 Cohort event monitoring 
Cohort event monitoring (CEM) involves the prospective study of the ADRs associated with a specific 
drug within a small group of patients — a cohort. The primary benefit of CEM is realised when it is 
used to observe the effects of a new medicine in the early stages of post-marketing authorisation 
[10]. Although all PV activities are centrally focused on patient safety, CEM focuses on a specific 
medication for the time before and during the control period. 
3.1.3 Targeted spontaneous reporting 
Targeted spontaneous reporting (TSR) is a methodology similar to spontaneous reporting, but 
involving well- defined patient groups where healthcare professionals (HCPs) are on the lookout for 
specific ADRs [10]. TSR is an active method of surveillance in a well-defined population group, 
whereas spontaneous reporting is a passive method of surveillance used within an undefined 
population [13]. Being an active surveillance method, TSR is more resource-intensive than 
spontaneous reporting. However, TSR produces reporting data of a higher standard. TSR methods 
have shown strong potential in low- and middle-income countries for the monitoring of drug safety 
over extended periods of time in populations with specific disease burdens, such as HIV and TB [14]. 
3.2 Effects of a lack of standardisation 
A brief summary of all the issues related to the lack of standardisation is presented here. The likely 
impact of standardisation on the various stages of the PV reporting system will be discussed in the 
next section. The most widespread challenge facing PV is a high level of under-reporting 
([15],[16],[17],[18],[12]), typically attributed to a lack of knowledge, time, and incentive 
([19],[16],[20]), which alludes to the lack of standardised reporting protocols and methodologies. 
PV also faces socio-cultural challenges, such as the existence of a culture of fear surrounding the 
reporting of ADRs due to a fear of undue disciplinary action being taken against HCPs ([21],[22],[19]). 
The literature also highlights the urgent need for educational awareness about PV activities and the 
simplification of the ADR reporting process to improve public participation ([23],[24],[25],[11]). 
Accountability among all stakeholders in a health system is important for the overall successful 
functioning of the system. A systematic review of ADR reporting systems by Bailey et al. [8] found a 
high degree of variability, with 1,782 distinct data elements having been identified across 108 
systems. This shows that ADR report forms need to have standardised terminology and a 
comprehensive set of unique data elements. 
3.3 What is meant by a standardised reporting system? 
Given the scope of this research, a standardised reporting system is envisioned to have the following 
characteristics: 
 
 A global system in which an ADR is reported once, with data of high quality to facilitate 
causality analysis;  
 A transparent system in which data is accessible by all stakeholders, including public health 
programmes (PHPs), regulatory authorities (RAs), manufacturers, HCPs, patients, and the 
public at large;  
 A system that ensures the confidentiality of patients; 
 A system that reduces the fragmentation and duplication of data and resources;  
 A system that improves resource use in resource-limited contexts;  
 A system that reduces administrative pressure, allowing HCPs to direct their attention to other 
priorities and giving them more time to report ADRs; and  





The objectives of this system would be: 
 
 To reduce the frequency and severity of ADRs by widening the scope of pharmacovigilance on 
a global level; 
 To improve causality analysis and risk assessment, allowing HCPs to make more informed 
therapeutic decisions; 
 To enable quantitative conclusions to be made about the safety of medicines for long-term 
use; and 
 To improve the communication of drug safety information between HCPs and patients; 
4 ANALYSIS, AND THE EFFECTS OF THE LACK OF A STANDARDISED GLOBAL PV REPORTING 
SYSTEM 
ADRs are a significant cause of morbidity, mortality, and increasing costs for PHPs [26]. By 
facilitating the communication and collation of comprehensive ADR data, the objectives of PV 
reporting can be achieved. These objectives include characterising known reactions, measuring risk, 
identifying new reactions by detecting signals, characterising drug interactions, identifying risk 
factors such as age, gender, dosage etc., assessing safety in various patient groups (pregnancy, 
elderly, paediatric, etc.), and detecting and measuring the inefficacy of medicines. 
 
Data pooling has a direct effect on the accuracy of ADR frequency estimation. By not pooling data 
from across the international landscape, we lessen the rate of detection of rare but clinically 
significant ADRs [27], specifically those that occur with a low incidence rate but that can pose a 
significant threat to public and patient safety. By pooling data, these silent but serious ADRs can be 
more readily detected. 
 
Patel et al. [28] found that the mean preventable ADRs leading to hospitalisation was 45.11 per 
cent, with the primary suspects being cardiovascular system drugs (28.1 per cent), nonsteroidal anti-
inflammatory drugs (NSAIDs) (16.1 per cent), nervous system drugs (16.9 per cent), and 
musculoskeletal drugs (16.1 per cent). Inappropriate drug selection due to misdiagnosis, toxic drug 
serum levels, and failure to predict or avoid known drug interactions are among the leading causes 
of preventable ADRs. 
 
A multitude of complex challenges hinder pharmacovigilance activities. Table 1 shows a breakdown 
of the challenges, and the part of the PV system with which they are associated [29]. The colour 
grading scale (added to the table as part of this research on the value of standardising ADR reporting) 
shows the extent to which a standardised ADR reporting system would alleviate the respective 
challenges. The colour gradings are explained and motivated in the subsections below. 
 
It is important to consider the limitations of spontaneous reporting systems. Due to the unsolicited 
nature of spontaneous reporting, problems such as under-reporting, the inability to derive incidence 
and prevalence rates due to the lack of denominator data, and the potential for reports to contain 
insufficient clinical data are widespread. 
  
 83 
Table 1: Breakdown of challenges facing different stages of the PV system (adapted from 
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A systematic review performed by Hazell and Shakir [17] provided evidence of widespread under-
reporting across 12 countries, and stated that the rate of under-reporting was as high as 94 per cent. 
The notion of under-reporting in the literature has often been attributed to the knowledge, 
attitudes, and practices [23] of healthcare providers. Common concerns and barriers to reporting by 
healthcare providers have been identified. These include lack of knowledge of the functioning of a 
PV system, lack of incentive to report ADRs, lack of time, and, interestingly, a fear of blame [21]. 
Healthcare providers, particularly in low-income countries, have been found to be reluctant to 
report ADRs, as they believe it reflects poorly on their professional ability to treat their patients 
[16]. A standardised reporting system would assist in restoring confidence in both healthcare 
providers and patients by ensuring the confidentiality of submitted reports. 




Through standardising the PV reporting system and associated protocols, PV in general will become 
easier to include, and more manageable, in all undergraduate training curricula of HCPs. The 
concept of a minimum requirement report is worth further investigation. This form would seek to 
capture the most important characteristics of the ADR, of the medication, and of the patient. If a 
more detailed follow-up report must be filed, the HCP and the patient would be notified accordingly. 
HCPs often cite a lack of time as a primary reason for not filling out ADR reports; a minimum 
requirement form would be less time-consuming to complete, and could therefore improve under-
reporting rates. Additional reflections on the expected impact of a minimum reporting form on 
resource utilisation follows in Section 4.6. 
 
A further improvement would be the use of a feedback mechanism to provide the HCP and patient 
with an acknowledgement of receipt of the ADR report. The provision of feedback to reporters of 
ADRs would almost certainly increase the overall rate of spontaneous reporting among HCPs and 
patients alike. This feedback could comprise a simple acknowledgement of receipt, or could provide 
information to the reporter about an appropriate course of action to take in order to treat the 
symptoms of the ADR experienced by the patient. 
4.2 Culture and transparency 
There is a need for a change in culture and transparency in ADR reporting [30]. There is a 
misconception among many healthcare practitioners, particularly those in low- and middle-income 
countries ([23],[31]), that pharmacovigilance is not the responsibility of a public health programme, 
but rather that of the pharmaceutical industry itself. Transparency is improving in PV systems around 
the globe, with some countries (such as Canada and the Netherlands) making their spontaneous 
reporting databases freely accessible to the public [32]. It is important to understand the distinction 
between transparency and confidentiality, and how they do not necessarily contradict one another. 
 
A transparent system would enable all stakeholders to interact with the system and to extract all 
the ADR data that pertains to their role in the PV system. Confidentiality of patient information can 
be achieved by not disclosing information to unauthorised parties. In the PV context, there are 
certain elements of an ADR report that should be disclosed to all stakeholders, but there are some 
that contain sensitive information about the patient. By ensuring the anonymity of patients when 
sharing their ADR report data, they can be confident that the generated data will not be used against 
them by any third party. 
 
Standardisation would improve the transparency of the system and improve the accessibility of up-
to-date information about the safety of medicines. Improving accessibility to the latest information 
would allow patients to have a greater degree of confidence in their PHP. Accountability can be 
improved through improving the knowledge, attitudes, and practices of HCPs during their 
undergraduate training. When HCPs understand that the responsibility of PV is shared by all 
stakeholders in the health system, they will be able to report ADRs, confident that their actions will 
not result in undue disciplinary action being taken against them. 
4.3 Public participation 
Patient-centricity is a key aspect of an effective PV system. Through fostering an environment in 
which the patient is well-informed and confident, public participation is likely to improve. PHPs 
need to provide accurate and transparent information to the public to gain public trust; a notable 
example of this is with national immunisation programmes. For the public to cooperate with a 
national programme for immunisation, the risks and benefits of the programme must be adequately 
communicated. 
 
An electronic web-based form should be made available to all members of the health system, and 
could be available in all languages to improve ease of use. As mentioned in Section 4.1, the use of 
a feedback mechanism to provide HCPs and patients with acknowledgement of receipt of their ADR 
report would likely improve levels of reporting. People will be more likely to participate in the 
system when they are made to feel valued by the system. Giving the patient a platform to make 
their voice heard and acknowledging their report is an important step in improving public 
participation. The encouragement of patient reporting would increase the rate of overall 
spontaneous reporting, and would likely enable earlier detection of unexpected ADRs [33]. 
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4.4 Lack of data  
Developing a standardised ADR spontaneous reporting framework would directly support the WHO’s 
efforts to manage pharmacovigilance activities on a global scale. An effective ADR spontaneous 
reporting system would allow for the early detection of ADRs in the post-marketing phase. Incidence 
rates of the ADRs could be established, and the identification and characterisation of novel drug 
interactions could take place. Bailey et al. [8] found a high degree of variability among the 108 
reporting systems in their study. They also pointed to the lack of standardised data elements in 
reporting forms, having identified 1,782 distinct data elements, which were mapped to 33 reporting 
concepts. A standardised reporting form would include a comprehensive list of unique data 
elements, prompting the extraction of all demographically and clinically relevant data relating to 
the patient and the ADR. 
 
This reduction in the number of data elements can be achieved through the use of standardised 
terminology. The two principal medical terminology directories are the Medical Dictionary for 
Regulatory Activities (MedDRA) and the World Health Organization Adverse Reactions Terminology 
Dictionary (WHO-ART). Discrepancies between MedDRA and WHO-ART contribute to the problem of 
data quality. A standardised reporting system would allow for improved causality analysis through 
the pooling of uniform data, extracted from a comprehensive set of unique data elements using 
standardised terminology. 
4.5 Proactive vs reactive system 
The unsolicited nature of spontaneous reporting makes it a reactive system. With 55 per cent of all 
drug label changes in the United States since 2010 being in direct response to spontaneous reporting 
of ADRs [12], it is clear that an improved reporting system can benefit proactive drug safety activities 
such as drug labelling and package inserts. By improving efficiency in ADR reporting, drug safety 
labels will reflect the latest safety information, allowing HCPs to make more informed therapeutic 
decisions. 
4.6 Lack of PV centres and insufficient resources 
Healthcare systems are unique to the countries in which they function. Pharmacovigilance activities, 
particularly in low- and middle-income countries (LMIC), are often considered ‘nice to have’, and 
take second place to efforts focused primarily on improving access to medicines [6]. Given the 
variety and complexity of public healthcare programmes around the world, the UMC faces 
considerable challenges and difficulties in attempting to co-ordinate the IDMP. A study by Olsson et 
al.[34] found that only 41 per cent of the countries studied had any budget allocated to 
pharmacovigilance. 
 
The lack of standardisation results in reporting systems receiving reports with incomplete or 
insufficient data. This places stress on the system and diverts resources such as time, people, and 
money away from other more important activities [20]. Accurately quantifying the cost of healthcare 
is difficult enough on a national public health programme level; assessing the costs associated with 
ADRs on a global level is even more challenging. However, research has been conducted to expose 
the reasons for these costs and to give estimates of the costs incurred by PHPs. 
 
Costs associated with ADRs are attributed to extended lengths of hospitalisation, the cost of treating 
illnesses caused by ADRs, and the cost of avoiding ADRs. Most of the literature on the 
pharmacoeconomic aspects of ADRs focuses primarily on the costs of the hospitalisation of patients 
due to ADRs. A 1998 study found that complications from ADRs account for the fourth to sixth leading 
cause of death in hospitalised patients in the United States of America [35]. Total hospital costs 
associated with ADRs in the US have been estimated to be at least $30 billion, and as high as $130 
billion, annually. 
 
By pooling resources among PHPs and drug manufacturers, a mechanism could be established to 
facilitate the follow-up of minimum requirement reports that have been received, as required. If 
sufficient minimum requirement reports, at an aggregate level, generate a signal that alludes to the 
presence of an unexpected ADR, then the appropriate resources can be allocated for a more 
thorough investigation into the safety of a specific medicine, such as a Cohort Event Monitoring 
initiative. 
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5 COMPONENTS AND MINIMUM REQUIREMENTS OF A STANDARDISED GLOBAL PV REPORTING 
SYSTEM 
The World Health Organization provides guidelines and a significant number of resources for 
conducting PV activities within PHPs. The minimum requirements for a functional PV system were 
first described in 2010 [36] and include, among other elements, a national spontaneous reporting 
system with an ADR reporting form. 
 
A standardised global PV reporting system (along with the standardised reporting form, such as the 
form described by Bailey et al. [8]) would rely heavily on the political will of the participating 
countries (together with the support of national regulatory agencies) to provide a clear legal basis 
and to inform all stakeholders of their relevant roles and responsibilities. Another critical success 
factor is the availability of stable funding, technical capability, and human resources for PV activities 
within the PHPs of the participating countries. 
 
The WHO cites the greatest challenge and responsibility of national PV centres within the public 
health programme to be the effective and open communication of drug safety information between 
the NRAs and the HCPs and patients [1]. The Erice Declaration of 1998 [1] serves as a framework to 
ensure that all stakeholders across the PV system act according to the highest ethical, professional, 
and scientific standards when communicating drug safety information. The Erice Declaration states 
the following: 
 
 Drug safety information must serve the health of the public. 
 Education in the appropriate use of drugs, including interpretation of safety information, is 
essential for the public at large, as well as for health care providers. 
 All the evidence needed to assess and understand risks and benefits must be openly available. 
 Every country needs a system with independent expertise to ensure that safety information on 
all available drugs is adequately collected, impartially evaluated, and made accessible to all. 
 Innovation in drug safety monitoring needs to ensure that emerging problems are promptly 
recognised and efficiently dealt with, and that information and solutions are effectively 
communicated. 
 
Informed HCPs and patients are encouraged to take up stewardship in carrying out PV activities and 
adhering to standards to ensure the successful communication of drug safety information. 
6 CONCLUSION 
Pharmacovigilance activities contribute to the prevention of unnecessary patient harm, improved 
clinical practice, and the support of research and education activities. Patient safety remains the 
central focus of all PV activities, with the end goal of assisting healthcare providers to make more 
informed therapeutic decisions for their patients. 
 
In order to identify and characterise evidence-based causal relationships between ADRs and their 
suspected medicines, standardised data must be communicated efficiently and effectively at every 
stage of the PV system. The standardised reporting system investigated in this research must be 
defined by experts and key stakeholders in the PV system. A thorough stakeholder analysis must be 
performed so that the perspectives of those stakeholders with a vested interest in the outcomes of 
the system — i.e., the regulators, healthcare providers, patients, etc. — are not neglected. 
 
The development of a standardised ADR spontaneous reporting framework would directly support 
the WHO’s efforts to manage pharmacovigilance activities on a global scale. If regional differences 
are insuperable, or a universal solution is not found to be feasible, the sharing of best practices, 
together with the leveraging of PV capacity and capability through collaboration and partnership, 
must be considered. Governments and their respective regulatory bodies need to provide a political 
mandate to all street-level bureaucrats, together with supporting legislation and standard operating 
procedures (SOPs), to improve awareness of, and adherence to, good PV practices across all levels 
of their public health programmes (PHPs). 
 
A collaborative global effort is needed to fast-track PV development around the world. Those 
countries without the necessary facilities, expertise, or resources for PV need them the most [31]. 
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Developing countries often have the highest disease burden on their PHPs. The strength of global 
pharmacovigilance lies in the integration of various national PV systems. Although efforts may have 
been made to standardise parts of the PV system, the focus must shift to the diffusion and successful 
adoption and implementation of those standards. 
 
REFERENCES 
[1] World Health Organization. 2002. The importance of pharmacovigilance: Safety monitoring of medicinal 
products. Geneva, Switzerland: World Health Organization. 
[2] Pirmohamed, M., Breckenridge, A.M., Kitteringham, N.R. and Park, B.K. 1998. Fortnightly review: 
Adverse drug reactions. British Medical Journal, 316(7140), p.1295. 
[3] Strengthening Pharmaceutical Systems (SPS). 2009. Supporting pharmacovigilance in developing 
countries: The systems perspective. Submitted to the US Agency for International Development by the SPS 
Program. Arlington: Management Sciences for Health. 
[4] Blind, K. and Mangelsdorf, A. 2016. Motives to standardize: Empirical evidence from 
Germany. Technovation, 48, pp.13-24.  
[5] Xie, Z., Hall, J., McCarthy, I.P., Skitmore, M. and Shen, L. 2016. Standardization efforts: The relationship 
between knowledge dimensions, search processes and innovation outcomes. Technovation, 48, pp.69-78. 
[6] Olsson, S., Pal, S.N. and Dodoo, A. 2015. Pharmacovigilance in resource-limited countries. Expert review 
of clinical pharmacology, 8(4), pp.449-460. 
[7] Banerjee, A.K., Okun, S., Edwards, I.R., Wicks, P., Smith, M.Y., Mayall, S.J., Flamion, B., Cleeland, C. 
and Basch, E. 2013. Patient-reported outcome measures in safety event reporting: PROSPER consortium 
guidance. Drug safety, 36(12), pp.1129-1149. 
[8] Bailey, C., Peddie, D., Wickham, M.E., Badke, K., Small, S.S., Doyle‐Waters, M.M., Balka, E. and Hohl, 
C.M. 2016. Adverse drug event reporting systems: A systematic review. British Journal of Clinical 
Pharmacology, 82(1), pp.17-29.  
[9] Ndagije, H., Nambasa, V., Namagala, E., Nassali, H., Kajungu, D., Sematiko, G., Olsson, S. and Pal, S. 
2015. Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-
retroviral therapy in two public health facilities in Uganda. Drug Safety, 38(4), pp.395-408. 
[10] Pal, S.N., Duncombe, C., Falzon, D. and Olsson, S. 2013. WHO strategy for collecting safety data in public 
health programmes: Complementing spontaneous reporting systems. Drug Safety, 36(2), pp.75-81. 
[11] Layton, D. and Shakir, S.A. 2015. Specialist cohort event monitoring studies: A new study method for risk 
management in pharmacovigilance. Drug Safety, 38(2), pp.153-163. 
[12] Lester, J., Neyarapally, G.A., Lipowski, E., Graham, C.F., Hall, M. and Dal Pan, G. 2013. Evaluation of 
FDA safety‐related drug label changes in 2010. Pharmacoepidemiology and Drug Safety, 22(3), pp.302-305. 
[13] Mehta, U., Dheda, M., Steel, G., Blockman, M., Ntilivamunda, A., Maartens, G., Pillay, Y. and Cohen, 
K. 2014. Strengthening pharmacovigilance in South Africa. South African Medical Journal, 104(2), pp.104-
106. 
[14] Pal, S.N., Olsson, S. and Brown, E.G. 2015. The monitoring medicines project: A multinational 
pharmacovigilance and public health project. Drug Safety, 38(4), pp.319-328.  
[15] Koutkias, V.G. and Jaulent, M.C. 2015. Computational approaches for pharmacovigilance signal detection: 
Toward integrated and semantically-enriched frameworks. Drug Safety, 38(3), pp.219-232. 
[16] Graham, J.E., Borda-Rodriguez, A., Huzair, F. and Zinck, E. 2012. Capacity for a global vaccine safety 
system: The perspective of national regulatory authorities. Vaccine, 30(33), pp.4953-4959. 
[17] Hazell, L. and Shakir, S.A. 2006. Under-reporting of adverse drug reactions. Drug Safety, 29(5), pp.385-
396. 
[18] Marques, F.B., Penedones, A., Mendes, D. and Alves, C. 2016. A systematic review of observational 
studies evaluating costs of adverse drug reactions. ClinicoEconomics and Outcomes Research, 8, p.413. 
[19] Hasford, J., Goettler, M., Munter, K.H. and Müller-Oerlinghausen, B. 2002. Physicians' knowledge and 
attitudes regarding the spontaneous reporting system for adverse drug reactions. Journal of Clinical 
Epidemiology, 55(9), pp.945-950. 
[20] Dal Pan, G.J. 2014. Ongoing challenges in pharmacovigilance. Drug Safety, 37(1), pp.1-8. 
[21] Kim, J., Kim, S., Jung, Y. and Kim, E.K. 2010. Status and problems of adverse event reporting systems in 
Korean hospitals. Healthcare Informatics Research, 16(3), pp.166-176. 
[22] Suku, C.K., Hill, G., Sabblah, G., Darko, M., Muthuri, G., Abwao, E., Pandit, J., Osakwe, A.I., Elagbaje, 
C., Nyambayo, P. and Khoza, S. 2015. Experiences and lessons from implementing cohort event monitoring 
programmes for antimalarials in four African countries: Results of a questionnaire-based survey. Drug 
Safety, 38(11), pp.1115-1126. 
[23] Bhagavathula, A.S., Elnour, A.A., Jamshed, S.Q. and Shehab, A. 2016. Health professionals' knowledge, 
attitudes and practices about pharmacovigilance in India: A systematic review and meta-analysis. PloS 
One, 11(3), p.e0152221.  
[24] Sevene, E., Mariano, A., Mehta, U., Machai, M., Dodoo, A., Vilardell, D., Patel, S., Barnes, K. and 
Carné, X. 2008. Spontaneous adverse drug reaction reporting in rural districts of Mozambique. Drug 
Safety, 31(10), pp.867-876. 
[25] Stergiopoulos, S., Brown, C.A., Felix, T., Grampp, G. and Getz, K.A. 2016. A survey of adverse event 




[26] Nazer, L.H., Eljaber, R., Rimawi, D. and Hawari, F.I. 2013. Adverse drug events resulting in admission to 
the intensive care unit in oncology patients: Incidence, characteristics and associated cost. Journal of 
Oncology Pharmacy Practice, 19(4), pp.298-304.  
[27] Olsson, S. 1998. The role of the WHO programme on international drug monitoring in coordinating 
worldwide drug safety efforts. Drug Safety, 19(1), pp.1-10. 
[28] Patel, N.S., Patel, T.K., Patel, P.B., Naik, V.N. and Tripathi, C.B. 2017. Hospitalizations due to 
preventable adverse reactions: A systematic review. European Journal of Clinical Pharmacology, 73(4), 
pp.1-14. 
[29] Lamprecht, I.V.B., Bam, L. and de Kock, I.H. 2017. An investigation into the prospects of existing 
technologies to address the challenges faced by pharmacovigilance systems, in Taking up stewardship — 
The 28th Annual SAIIE Conference 2017 Proceedings, Vanderbijlpark, South Africa, October 25-27, 2017. 
[30] Chruscicki, A., Badke, K., Peddie, D., Small, S., Balka, E. and Hohl, C.M. 2016. Pilot-testing an adverse 
drug event reporting form prior to its implementation in an electronic health record. SpringerPlus, 5(1), 
p.1764. 
[31] World Health Organization. 2006. Pharmacovigilance an essential tool. Geneva: World Health 
Organization. 
[32] Molokhia, M., Tanna, S. and Bell, D. 2009. Improving reporting of adverse drug reactions: Systematic 
review. Clinical Epidemiology, 1, p.75. 
[33] Jarernsiripornkul, N., Patsuree, A. and Krska, J. 2017. Public confidence in ADR identification and their 
views on ADR reporting: Mixed methods study. European Journal of Clinical Pharmacology, 73(2), pp.223-
231. 
[34] Olsson, S., Pal, S.N., Stergachis, A. and Couper, M. 2010. Pharmacovigilance activities in 55 low-and 
middle-income countries. Drug Safety, 33(8), pp.689-703. 
[35] Lazarou, J., Pomeranz, B.H. and Corey, P.N. 1998. Incidence of adverse drug reactions in hospitalized 
patients: A meta-analysis of prospective studies. The Journal of the American Medical 
Association, 279(15), pp.1200-1205. 
[36] World Health Organization. 2010. Minimum requirements for a functional pharmacovigilance system. 
Geneva: World Health Organization. 
[37] Maggo, S.D., Savage, R.L. and Kennedy, M.A. 2016. Impact of new genomic technologies on understanding 
adverse drug reactions. Clinical Pharmacokinetics, 55(4), pp.419-436. 
 
 
